Seagen Founder Clay Siegall Named CEO of Purdue Spinout Morphimmune After Resigning in 2023
Clay Siegall, founder and former CEO of Seagen, has returned to biotech as CEO and president of Morphimmune, a Purdue University spinout relocating to Seattle. This move follows his resignation from Seagen in May 2023 and precedes Pfizer's planned $43 billion acquisition of Seagen.
More: GeekWire
-
GeekWire / Charlotte Schubert: Seagen Founder Clay Siegall Returns as CEO of Purdue Spinout After Pfizer's $43B Acquisition Deal